![Abhinav Jain](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Abhinav Jain
Directeur/Membre du Conseil chez
AYTU BIOPHARMA, INC.
Fortune : 144 351 $ au 31/08/2026
Profil
Abhinav Jain is currently an Independent Director at Aytu Biopharma, Inc. since 2023, Talphera, Inc. since 2024, and at both Xtant Medical Holdings, Inc. and Eagle Pharmaceuticals, Inc. starting in 2025.
Formerly, Mr. Jain was an Associate at Angelo, Gordon & Co. LP.
from 2015 to 2017.
Education includes an undergraduate degree from the Massachusetts Institute of Technology in 2012 and an MBA from The Wharton School of the University of Pennsylvania in 2019.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AYTU BIOPHARMA, INC. 0,27 % | 28/07/2026 | 29 500 ( 0,27 % ) | 67 555 $ | 31/08/2026 |
| 15/08/2026 | 158 228 ( 0,11 % ) | 62 025 $ | 31/08/2026 | |
TALPHERA, INC. 0,02 % | 22/06/2026 | 12 412 ( 0,02 % ) | 14 770 $ | 31/08/2026 |
Postes actifs de Abhinav Jain
| Sociétés | Poste | Début |
|---|---|---|
| AYTU BIOPHARMA, INC. | Directeur/Membre du Conseil | 12/06/2023 |
| TALPHERA, INC. | Directeur/Membre du Conseil | 22/01/2024 |
| XTANT MEDICAL HOLDINGS, INC. | Directeur/Membre du Conseil | 01/08/2025 |
| EAGLE PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 28/08/2025 |
Anciens postes connus de Abhinav Jain
| Sociétés | Poste | Fin |
|---|---|---|
Angelo, Gordon & Co. LP
 Angelo, Gordon & Co. LP Investment ManagersFinance TPG Angelo Gordon seeks alternative investment opportunities that will deliver consistent absolute returns for their clients. The firm manages capital across their Credit and Real Estate strategies, all of which employ a disciplined investment philosophy that combines fundamental in-depth research with a diversification strategy 20 designed to reduce downside risk. The research team is the cornerstone of all investment activities. | Corporate Officer/Principal | 01/01/2017 |
Formation de Abhinav Jain
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
98
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Angelo, Gordon & Co. LP
Angelo, Gordon & Co. LP Investment ManagersFinance TPG Angelo Gordon seeks alternative investment opportunities that will deliver consistent absolute returns for their clients. The firm manages capital across their Credit and Real Estate strategies, all of which employ a disciplined investment philosophy that combines fundamental in-depth research with a diversification strategy 20 designed to reduce downside risk. The research team is the cornerstone of all investment activities. | Finance |
Eagle Pharmaceuticals, Inc.
 Eagle Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercialize injectable products primarily in the metabolic critical care and oncology | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Talphera, Inc.
 Talphera, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aytu Biopharma, Inc.
 Aytu Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Xtant Medical Holdings, Inc.
 Xtant Medical Holdings, Inc. Medical SpecialtiesHealth Technology Manufactures and commercializes surgical products | Health Technology |
